Company: CNTB
Filing Date: 2025-07-09
Form Type: 8-K
Source: 0001628280-25-034551
Chunk: 0

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-07-09
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01 Regulation FD Disclosure.

On July 9, 2025, Connect Biopharma Holdings Limited (the “ Company”) issued a press release announcing that the Company’s collaborator and exclusive licensee in China, Simcere Pharmaceutical Co., Ltd. (“ Simcere”), has submitted its New Drug Application (“ NDA”) for rademikibart to the National Medical Products Administration of China (“ NMPA”) for the treatment of atopic dermatitis (“ AD”) in adults and adolescents. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated into this Item 7.01 by reference.

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.